Loading
Combining a BRAF inhibitor with a MEK inhibitor shrank tumours in about two thirds of previously treated patients with BRAF V600E-mutant lung cancer, far more than BRAF inhibition alone, leading to the first approval for this driver.
Phase 2 multicohort study; this cohort treated 57 patients with previously treated BRAF V600E-mutant metastatic non-small-cell lung cancer with dabrafenib plus trametinib.
Objective response was 63.2 percent with a median progression-free survival of 9.7 months, compared with 33 percent for dabrafenib alone in an earlier cohort; pyrexia, nausea and fatigue were common.
BRAF V600E is a routinely tested lung cancer driver, and BRAF plus MEK inhibition is the standard targeted therapy for it.
Shares BRAF V600E-mutant non-small-cell lung cancer, Dabrafenib, Trametinib, The Lancet Oncology.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares BRAF V600E-mutant non-small-cell lung cancer, Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Shares Dabrafenib, Trametinib.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/